HUP1100535A2 - Pharmaceutical composition for enhancement of stem cell treatment - Google Patents

Pharmaceutical composition for enhancement of stem cell treatment

Info

Publication number
HUP1100535A2
HUP1100535A2 HU1100535A HUP1100535A HUP1100535A2 HU P1100535 A2 HUP1100535 A2 HU P1100535A2 HU 1100535 A HU1100535 A HU 1100535A HU P1100535 A HUP1100535 A HU P1100535A HU P1100535 A2 HUP1100535 A2 HU P1100535A2
Authority
HU
Hungary
Prior art keywords
enhancement
pharmaceutical composition
stem cell
cell treatment
treatment
Prior art date
Application number
HU1100535A
Other languages
Hungarian (hu)
Inventor
Balazs Dr Hazay
Original Assignee
Bracelia Invest Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracelia Invest Ltd filed Critical Bracelia Invest Ltd
Priority to HU1100535A priority Critical patent/HUP1100535A2/en
Priority to PCT/HU2012/000098 priority patent/WO2013045963A1/en
Priority to EP12805749.4A priority patent/EP2760449A1/en
Publication of HUP1100535A2 publication Critical patent/HUP1100535A2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0652Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662Stem cells
    • C12N5/0663Bone marrow mesenchymal stem cells (BM-MSC)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/07Heat shock proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70Enzymes
    • C12N2501/72Transferases [EC 2.]
    • C12N2501/727Kinases (EC 2.7.)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU1100535A 2011-09-26 2011-09-26 Pharmaceutical composition for enhancement of stem cell treatment HUP1100535A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
HU1100535A HUP1100535A2 (en) 2011-09-26 2011-09-26 Pharmaceutical composition for enhancement of stem cell treatment
PCT/HU2012/000098 WO2013045963A1 (en) 2011-09-26 2012-09-25 A pharmaceutical composition for the treatment of stem cells
EP12805749.4A EP2760449A1 (en) 2011-09-26 2012-09-25 A pharmaceutical composition for the treatment of stem cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU1100535A HUP1100535A2 (en) 2011-09-26 2011-09-26 Pharmaceutical composition for enhancement of stem cell treatment

Publications (1)

Publication Number Publication Date
HUP1100535A2 true HUP1100535A2 (en) 2013-04-29

Family

ID=89990452

Family Applications (1)

Application Number Title Priority Date Filing Date
HU1100535A HUP1100535A2 (en) 2011-09-26 2011-09-26 Pharmaceutical composition for enhancement of stem cell treatment

Country Status (3)

Country Link
EP (1) EP2760449A1 (en)
HU (1) HUP1100535A2 (en)
WO (1) WO2013045963A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP1800298A1 (en) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Combination of beta blocker and hydroximic acid derivative with reduced side effects

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU207988B (en) 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
HU222994B1 (en) 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hydroxylamine derivatives and use thereof in the preparation of a pharmaceutical compositions for enhancing of molecular chaperon production of cells
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells
HUP9900475D0 (en) 1999-02-26 1999-04-28 Biorex Kutato Fejlesztoe Kft O-(3-piperidino-2-hydroxy-1-propyl)-hiyroximic acid-halogenid derivative, it's use for treating insulin resistance, and pharmaceutical compositions containing them as active component
HUP0001583A2 (en) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. A pyridine-1-oxide derivative and process for its conversion to medicinal compounds
US8540985B2 (en) * 2008-06-26 2013-09-24 Orphazyme Aps Use of Hsp70 as a regulator of enzymatic activity
US20110027771A1 (en) * 2009-07-31 2011-02-03 Artemis Health, Inc. Methods and compositions for cell stabilization

Also Published As

Publication number Publication date
WO2013045963A1 (en) 2013-04-04
EP2760449A1 (en) 2014-08-06

Similar Documents

Publication Publication Date Title
EP2771030A4 (en) Compositions and methods for treatment of proteinopathies
PT2714059T (en) Treatment of pain using placental stem cells
PL2740796T3 (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740794T (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer
EP2675458A4 (en) Compounds and methods for treatment of hypertension
EP2773754A4 (en) Method of treatment
GB201106960D0 (en) Treatment of waste
IL233111A0 (en) Treatment of inflammation
SI2691083T1 (en) Pharmaceutical composition of sitagliptin
GB201202773D0 (en) Compositions for treatment of skin disorders
SG10201605205VA (en) Treatment of rhinitis
HUE038787T2 (en) Tripeptide compositions and their use for treatment of diabetes
ZA201304743B (en) Method for enhancing engraftment of haematopoetics stem cells
EP2704702A4 (en) Composition and method for treatment of diabetes
IL234606A0 (en) Novel methods and composition for treatment of disease
EP2670243A4 (en) Compositions and methods for treatment of glaucoma
IL232065A (en) Pharmaceutical composition for treatment of adrenal insufficiency
IL231143A0 (en) Treatment of rhinitis
PH12014501052A1 (en) Methods and compositions for the treatment of diabetes and related symptoms
IL222072A (en) Composition for treatment of essential thrombocythemia
HUP1100535A2 (en) Pharmaceutical composition for enhancement of stem cell treatment
ZA201400956B (en) Treatment of sulphidic materials
ZA201409502B (en) Composition for treatment of warts
EP2785380A4 (en) Treatment of b cell lymphomas
EP2791324A4 (en) Method of treatment

Legal Events

Date Code Title Description
RH9A Decision on the lapse of patent protection withdrawn
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished
GB9A Succession in title

Owner name: BRACELIA INVESTMENTS LIMITED, CY

Free format text: FORMER OWNER(S): DR. HAZAY BALAZS, HU